Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the acceptance of a new single-center retrospective study in Frontiers in Pediatrics, a multi-disciplinary peer-reviewed journal that addresses challenges in pediatric patient care and child health, demonstrating that epoprostenol may serve as a safe and feasible alternative anticoagulant during Aquadex therapy in critically ill pediatric patients. The study, "Epoprostenol as an Alternative Anticoagulant for Pediatric Aquadex Therapy: A Safe and Feasible Option," reports the first documented use of epoprostenol, a short-acting drug that prevents platelet clumping, as the sole anticoagulant for children undergoing Aquadex ultrafiltration therapy in the intensive care unit. In the critically ill children studied, the approach maintained the filtering circuit, did not increase the need for blood-pressure support, and was not associated with any bleeding events.